BIIB SEC filings (2026)
CIK 875045 · Biological Products, (No Diagnostic Substances) (SIC 2836) · incorporated in DE · fiscal year ends in December
2,712 filings on EDGAR since 1996 · 34 annual, 95 quarterly, 298 current · financial statements · earnings
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
August 2026
July 2026
- Jul 29EarningsEarnings release — EPS $3.60 vs $3.04 est. (+18.4%); revenue $2.74B (+3% y/y) 1.8%
- Jul 29ReportQuarterly report, Q2 2026 — revenue $2.74B (+3% y/y), net income $97.5M, EPS $0.66
- Jul 18-K8-K · Results of operations
June 2026
- Jun 108-K8-K · Shareholder vote results
- Jun 108-K8-K · Financial statements and exhibits
May 2026
- May 148-K8-K · Biogen Completes Acquisition of Apellis PharmaceuticalsMaterial definitive agreement; Completion of an acquisition or disposition; New financial obligation; Regulation FD disclosure
April 2026
- Apr 29EarningsEarnings release — EPS $3.57 vs $2.95 est. (+21.0%); revenue $2.48B (+2% y/y) 6.0%
- Apr 29ReportQuarterly report, Q1 2026 — revenue $2.48B (+2% y/y), net income $319.5M, EPS $2.15
- Apr 28ProxyProxy · Annual report to shareholders
- Apr 28ProxyProxy · Additional proxy materials
- Apr 28ProxyProxy · Proxy statement
- Apr 68-K8-K · Results of operations
March 2026
- Mar 318-K8-K · Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyMaterial definitive agreement; Other events
- Mar 118-K8-K · Directors or officers; compensation
February 2026
- Feb 12Insider buyMurphy Nicole (Head of Pharm Ops and Tech) bought 3 shares for $585 at $195.04
- Feb 118-K8-K · Directors or officers; compensation; Other events
- Feb 9Insider saleSinghal Priya (Head of Development) sold 2,660 shares for $532K at $199.83 under a 10b5-1 plan
- Feb 6EarningsEarnings release — EPS $1.99 vs $1.61 est. (+23.6%); revenue $2.28B (−7% y/y) 8.5%
- Feb 6ReportAnnual report, FY2025 — revenue $9.89B (+2% y/y), net income $1.29B, EPS $8.79
- Feb 2Insider saleSinghal Priya (Head of Development) sold 748 shares for $134K at $179.30 under a 10b5-1 plan
January 2026
- Jan 148-K8-K · Results of operations
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $905K in 4 sales and bought $585 in 1 purchase; 65 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Aug 4, 2026Form 4 | Minor LloydDirectorSold · $119K · 593 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Minor LloydDirectorSold · $121K · 593 sh · 10b5-1 |
| Feb 12, 2026Form 4 | Murphy NicoleHead of Pharm Ops and TechBought · $585 · 3 sh |
| Feb 9, 2026Form 4 | Singhal PriyaHead of DevelopmentSold · $532K · 2,660 sh · 10b5-1 |
| Feb 2, 2026Form 4 | Singhal PriyaHead of DevelopmentSold · $134K · 748 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 65 transactions
| Date | Insider |
|---|---|
| Oct 2, 2026Form 4 | Godbout SeanChief Accounting OfficerTax withholding · $1,759 · 8 sh |
| Oct 2, 2026Form 4 | Godbout SeanChief Accounting OfficerExercise or conversion · $0 · 27 sh |
| Oct 2, 2026Form 4 | Godbout SeanChief Accounting OfficerExercise or conversion · Restricted Stock Unit · $0 · 27 sh |
| Oct 1, 2026Form 4 | Godbout SeanChief Accounting OfficerAward · Restricted Stock Unit · $0 · 985 sh |
| Sep 1, 2026Form 4 | Parini MichaelChief Legal OfficerAward · Restricted Stock Unit · $0 · 7,405 sh |
| Jun 9, 2026Form 4 | Pangalos Menelas NDirectorExercise or conversion · $0 · 2,370 sh |
| Jun 9, 2026Form 4 | Pangalos Menelas NDirectorExercise or conversion · Restricted Stock Unit · $0 · 2,370 sh |
| Jun 9, 2026Form 4 | Freire Maria CDirectorAward · $0 · 2,005 sh |
| Jun 9, 2026Form 4 | Minor LloydDirectorAward · $0 · 1,505 sh |
| Jun 9, 2026Form 4 | Pangalos Menelas NDirectorAward · $0 · 1,505 sh |
| Jun 9, 2026Form 4 | Patolawala Monish DDirectorAward · $0 · 1,505 sh |
| Jun 9, 2026Form 4 | LANGER SUSANDirectorAward · $0 · 1,505 sh |
| Jun 9, 2026Form 4 | Mantas Jesus BDirectorAward · $0 · 1,505 sh |
| Jun 9, 2026Form 4 | Rowinsky Eric KDirectorAward · $0 · 1,505 sh |
| Jun 9, 2026Form 4 | SHERWIN STEPHEN ADirectorAward · $0 · 1,505 sh |
| Jun 9, 2026Form 4 | HAWKINS WILLIAM ADirectorAward · $0 · 1,505 sh |
| May 1, 2026Form 4 | Keeney AdamHead of Corporate DevelopmentTax withholding · $85K · 455 sh |
| May 1, 2026Form 4 | Keeney AdamHead of Corporate DevelopmentExercise or conversion · $0 · 939 sh |
| May 1, 2026Form 4 | Keeney AdamHead of Corporate DevelopmentExercise or conversion · Restricted Stock Unit · $0 · 939 sh |
| Apr 1, 2026Form 4 | Godbout SeanChief Accounting OfficerTax withholding · $9,924 · 54 sh |
| Apr 1, 2026Form 4 | Godbout SeanChief Accounting OfficerExercise or conversion · $0 · 181 sh |
| Apr 1, 2026Form 4 | Godbout SeanChief Accounting OfficerExercise or conversion · Restricted Stock Unit · $0 · 181 sh |
| Feb 13, 2026Form 4 | Viehbacher ChristopherPresident and CEO · DirectorAward · Restricted Stock Unit · $0 · 38,015 sh |
| Feb 13, 2026Form 4 | Murphy NicoleHead of Pharm Ops and TechAward · Restricted Stock Unit · $0 · 10,560 sh |
| Feb 13, 2026Form 4 | Singhal PriyaHead of DevelopmentAward · Restricted Stock Unit · $0 · 10,560 sh |
| Feb 13, 2026Form 4 | ALEXANDER SUSAN HEVP Chief Legal OfficerAward · Restricted Stock Unit · $0 · 8,450 sh |
| Feb 13, 2026Form 4 | Grogan JaneHead of ResearchAward · Restricted Stock Unit · $0 · 8,450 sh |
| Feb 13, 2026Form 4 | Kramer RobinChief Financial OfficerAward · Restricted Stock Unit · $0 · 8,450 sh |
| Feb 13, 2026Form 4 | Gregory GingerEVP, Human ResourcesAward · Restricted Stock Unit · $0 · 8,025 sh |
| Feb 13, 2026Form 4 | Keeney AdamHead of Corporate DevelopmentAward · Restricted Stock Unit · $0 · 8,025 sh |
| Feb 13, 2026Form 4 | Izzar RachidHead of Global Product Strat.Award · Restricted Stock Unit · $0 · 7,390 sh |
| Feb 13, 2026Form 4 | Godbout SeanChief Accounting OfficerAward · Restricted Stock Unit · $0 · 1,800 sh |
| Feb 6, 2026Form 4 | Viehbacher ChristopherPresident and CEO · DirectorTax withholding · $2.2M · 10,980 sh |
| Feb 6, 2026Form 4 | ALEXANDER SUSAN HEVP Chief Legal OfficerTax withholding · $705K · 3,504 sh |
| Feb 6, 2026Form 4 | Murphy NicoleHead of Pharm Ops and TechTax withholding · $672K · 3,339 sh |
| Feb 6, 2026Form 4 | Gregory GingerEVP, Human ResourcesTax withholding · $521K · 2,589 sh |
| Feb 6, 2026Form 4 | Singhal PriyaHead of DevelopmentTax withholding · $497K · 2,468 sh · 10b5-1 |
| Feb 6, 2026Form 4 | Izzar RachidHead of Global Product Strat.Tax withholding · $410K · 2,038 sh |
| Feb 6, 2026Form 4 | Keeney AdamHead of Corporate DevelopmentTax withholding · $318K · 1,583 sh |
| Feb 6, 2026Form 4 | Kramer RobinChief Financial OfficerTax withholding · $310K · 1,543 sh |
| Feb 6, 2026Form 4 | Grogan JaneHead of ResearchTax withholding · $199K · 991 sh |
| Feb 6, 2026Form 4 | Godbout SeanChief Accounting OfficerTax withholding · $72K · 359 sh |
| Feb 6, 2026Form 4 | Viehbacher ChristopherPresident and CEO · DirectorExercise or conversion · $0 · 24,461 sh |
| Feb 6, 2026Form 4 | Viehbacher ChristopherPresident and CEO · DirectorExercise or conversion · Restricted Stock Unit · $0 · 24,461 sh |
| Feb 6, 2026Form 4 | ALEXANDER SUSAN HEVP Chief Legal OfficerExercise or conversion · $0 · 9,046 sh |
| Feb 6, 2026Form 4 | ALEXANDER SUSAN HEVP Chief Legal OfficerExercise or conversion · Restricted Stock Unit · $0 · 9,046 sh |
| Feb 6, 2026Form 4 | Murphy NicoleHead of Pharm Ops and TechExercise or conversion · $0 · 8,725 sh |
| Feb 6, 2026Form 4 | Murphy NicoleHead of Pharm Ops and TechExercise or conversion · Restricted Stock Unit · $0 · 8,725 sh |
| Feb 6, 2026Form 4 | Gregory GingerEVP, Human ResourcesExercise or conversion · $0 · 7,183 sh |
| Feb 6, 2026Form 4 | Gregory GingerEVP, Human ResourcesExercise or conversion · Restricted Stock Unit · $0 · 7,183 sh |
| Feb 6, 2026Form 4 | Singhal PriyaHead of DevelopmentExercise or conversion · $0 · 6,900 sh · 10b5-1 |
| Feb 6, 2026Form 4 | Singhal PriyaHead of DevelopmentExercise or conversion · Restricted Stock Unit · $0 · 6,900 sh · 10b5-1 |
| Feb 6, 2026Form 4 | Izzar RachidHead of Global Product Strat.Exercise or conversion · $0 · 6,889 sh |
| Feb 6, 2026Form 4 | Izzar RachidHead of Global Product Strat.Exercise or conversion · Restricted Stock Unit · $0 · 6,889 sh |
| Feb 6, 2026Form 4 | Keeney AdamHead of Corporate DevelopmentExercise or conversion · $0 · 5,080 sh |
| Feb 6, 2026Form 4 | Keeney AdamHead of Corporate DevelopmentExercise or conversion · Restricted Stock Unit · $0 · 5,080 sh |
| Feb 6, 2026Form 4 | Kramer RobinChief Financial OfficerExercise or conversion · $0 · 5,003 sh |
| Feb 6, 2026Form 4 | Kramer RobinChief Financial OfficerExercise or conversion · Restricted Stock Unit · $0 · 5,003 sh |
| Feb 6, 2026Form 4 | Grogan JaneHead of ResearchExercise or conversion · $0 · 3,258 sh |
| Feb 6, 2026Form 4 | Grogan JaneHead of ResearchExercise or conversion · Restricted Stock Unit · $0 · 3,258 sh |
| Feb 6, 2026Form 4 | Godbout SeanChief Accounting OfficerExercise or conversion · $0 · 1,079 sh |
| Feb 6, 2026Form 4 | Godbout SeanChief Accounting OfficerExercise or conversion · Restricted Stock Unit · $0 · 1,079 sh |
| Jan 30, 2026Form 4 | Singhal PriyaHead of DevelopmentTax withholding · $105K · 582 sh · 10b5-1 |
| Jan 30, 2026Form 4 | Singhal PriyaHead of DevelopmentExercise or conversion · $0 · 1,829 sh · 10b5-1 |
| Jan 30, 2026Form 4 | Singhal PriyaHead of DevelopmentExercise or conversion · Restricted Stock Unit · $0 · 1,829 sh · 10b5-1 |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 18 filings
| Filed | What it is |
|---|---|
| Jul 29, 202610-Q | Quarterly report, Q2 2026 — revenue $2.74B (+3% y/y), net income $97.5M, EPS $0.66 |
| Jul 29, 20268-K | Earnings release — EPS $3.60 vs $3.04 est. (+18.4%); revenue $2.74B (+3% y/y) 1.8% |
| Jul 1, 20268-K | Results of operations |
| Jun 10, 20268-K | Shareholder vote results |
| Jun 10, 20268-K/A | Financial statements and exhibits |
| May 14, 20268-K | Biogen Completes Acquisition of Apellis PharmaceuticalsMaterial definitive agreement; Completion of an acquisition or disposition; New financial obligation; Regulation FD disclosure |
| Apr 29, 202610-Q | Quarterly report, Q1 2026 — revenue $2.48B (+2% y/y), net income $319.5M, EPS $2.15 |
| Apr 29, 20268-K | Earnings release — EPS $3.57 vs $2.95 est. (+21.0%); revenue $2.48B (+2% y/y) 6.0% |
| Apr 28, 2026ARS | Annual report to shareholders |
| Apr 28, 2026DEFA14A | Additional proxy materials |
| Apr 28, 2026DEF 14A | Proxy statement |
| Apr 6, 20268-K | Results of operations |
| Mar 31, 20268-K | Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyMaterial definitive agreement; Other events |
| Mar 11, 20268-K | Directors or officers; compensation |
| Feb 11, 20268-K | Directors or officers; compensation; Other events |
| Feb 6, 202610-K | Annual report, FY2025 — revenue $9.89B (+2% y/y), net income $1.29B, EPS $8.79 |
| Feb 6, 20268-K | Earnings release — EPS $1.99 vs $1.61 est. (+23.6%); revenue $2.28B (−7% y/y) 8.5% |
| Jan 14, 20268-K | Results of operations |
2025 · 17 filings
| Filed | What it is |
|---|---|
| Oct 30, 202510-Q | Quarterly report, Q3 2025 — revenue $2.53B (+3% y/y), net income $466.5M, EPS $3.17 |
| Oct 30, 20258-K | Earnings release — EPS $4.81 vs $3.89 est. (+23.6%); revenue $2.53B (+3% y/y) 1.2% |
| Oct 14, 20258-K | Results of operations |
| Jul 31, 20258-K | Earnings release — EPS $5.47 vs $3.93 est. (+39.2%); revenue $2.65B (+7% y/y) 1.1% |
| Jul 31, 202510-Q | Quarterly report, Q2 2025 — revenue $2.65B (+7% y/y), net income $634.8M, EPS $4.33 |
| Jul 7, 20258-K | Results of operations |
| Jun 23, 20258-K | Shareholder vote results |
| Jun 2, 2025DEFA14A | Additional proxy materials |
| May 12, 20258-K | Other events |
| May 1, 202510-Q | Quarterly report, Q1 2025 — revenue $2.43B (+6% y/y), net income $240.5M, EPS $1.64 |
| May 1, 20258-K | Earnings release — EPS $3.02 vs $3.26 est. (−7.4%); revenue $2.43B (+6% y/y) 0.1% |
| Apr 28, 2025ARS | Annual report to shareholders |
| Apr 28, 2025DEFA14A | Additional proxy materials |
| Apr 28, 2025DEF 14A | Proxy statement |
| Feb 12, 202510-K | Annual report, FY2024 — revenue $9.68B (−2% y/y), net income $1.63B, EPS $11.18 |
| Feb 12, 20258-K | Earnings release — EPS $3.44 vs $3.42 est. (+0.6%); revenue $2.45B (+3% y/y) 4.3% |
| Jan 15, 20258-K | Directors or officers; compensation |
2024 · 16 filings
| Filed | What it is |
|---|---|
| Oct 30, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Oct 30, 202410-Q | Quarterly report, Q3 2024 — revenue $2.47B (−3% y/y), net income $388.5M, EPS $2.66 |
| Oct 30, 20248-K | Earnings release — EPS $4.08 vs $3.77 est. (+8.2%); revenue $2.47B (−3% y/y) 1.2% |
| Sep 12, 20248-K | Directors or officers; compensation |
| Aug 14, 20248-K | Material definitive agreement; Termination of a material agreement; New financial obligation |
| Aug 1, 202410-Q | Quarterly report, Q2 2024 — revenue $2.46B (+0% y/y), net income $583.6M, EPS $4.00 |
| Aug 1, 20248-K | Earnings release — EPS $5.28 vs $4.00 est. (+32.0%); revenue $2.46B (+0% y/y) 1.2% |
| Jun 25, 20248-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| Apr 26, 2024ARS | Annual report to shareholders |
| Apr 26, 2024DEFA14A | Additional proxy materials |
| Apr 26, 2024DEF 14A | Proxy statement |
| Apr 24, 202410-Q | Quarterly report, Q1 2024 — revenue $2.29B (−7% y/y), net income $393.4M, EPS $2.70 |
| Apr 24, 20248-K | Earnings release — EPS $3.67 vs $3.45 est. (+6.4%); revenue $2.29B (−7% y/y) 4.6% |
| Apr 12, 2024PRE 14A | Preliminary proxy statement |
| Feb 14, 202410-K | Annual report, FY2023 — revenue $9.84B (−3% y/y), net income $1.16B, EPS $7.97 |
| Feb 13, 20248-K | Earnings release — EPS $2.95 vs $3.16 est. (−6.7%); revenue $2.39B (−6% y/y) 7.4% |
2023 · 27 filings — 14 × 8-K, 5 × DEFA14A, 3 × 10-Q and 5 other forms
| Filed | What it is |
|---|---|
| Nov 8, 202310-Q | Quarterly report, Q3 2023 — revenue $2.53B (+1% y/y), net income −$68.1M, EPS −$0.47 |
| Jul 31, 2023DEFA14A | Additional proxy materials |
| Jul 28, 2023DEFA14A | Additional proxy materials |
| Jul 25, 202310-Q | Quarterly report, Q2 2023 — revenue $2.46B, net income $591.6M, EPS $4.07 |
| Jun 13, 2023DEFA14A | Additional proxy materials |
| Jun 13, 2023DEFR14A | Proxy statements |
| Jun 12, 2023DEFA14A | Additional proxy materials |
| Apr 28, 2023DEFA14A | Additional proxy materials |
| Apr 28, 2023DEF 14A | Proxy statement |
| Apr 28, 2023ARS | Annual report to shareholders |
| Apr 25, 202310-Q | Quarterly report, Q1 2023 — revenue $2.46B (−3% y/y), net income $387.9M, EPS $2.67 |
| Feb 15, 202310-K | Annual report, FY2022 — revenue $10.17B (−7% y/y), net income $3.05B, EPS $20.87 |
15 current reports (8-K) not listed; the year is on EDGAR.
2022 · 15 filings — 7 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 25, 202210-Q | Quarterly report, Q3 2022 — revenue $2.51B (−10% y/y), net income $1.13B |
| Jul 20, 202210-Q | Quarterly report |
| Jun 7, 2022DEFA14A | Additional proxy materials |
| May 3, 202210-Q | Quarterly report, Q1 2022 — revenue $2.53B (−6% y/y), net income $303.8M, EPS $2.06 |
| Apr 29, 2022DEFA14A | Additional proxy materials |
| Apr 29, 2022DEF 14A | Proxy statement |
| Feb 3, 202210-K | Annual report, FY2021 — revenue $10.98B (−18% y/y), net income $1.56B, EPS $10.40 |
8 current reports (8-K) not listed; the year is on EDGAR.
2021 · 19 filings — 10 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
| Filed | What it is |
|---|---|
| Oct 20, 202110-Q | Quarterly report, Q3 2021 — revenue $2.78B (−18% y/y), net income $329.2M, EPS $2.22 |
| Jul 22, 202110-Q | Quarterly report, Q2 2021 — revenue $2.77B (−25% y/y), net income $448.5M, EPS $2.99 |
| May 28, 2021PX14A6G | Shareholder exempt solicitation |
| Apr 23, 2021DEFA14A | Additional proxy materials |
| Apr 23, 2021DEF 14A | Proxy statement |
| Apr 22, 202110-Q | Quarterly report, Q1 2021 — revenue $2.69B (−24% y/y), net income $410.2M, EPS $2.69 |
| Apr 9, 2021PRE 14A | Preliminary proxy statement |
| Apr 9, 2021DEFA14A | Additional proxy materials |
| Feb 3, 202110-K | Annual report, FY2020 — revenue $13.44B (−6% y/y), net income $4.00B, EPS $24.80 |
10 current reports (8-K) not listed; the year is on EDGAR.
2020 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 21, 202010-Q | Quarterly report, Q3 2020 — revenue $3.38B (−6% y/y), net income $701.5M, EPS $4.46 |
| Jul 22, 202010-Q | Quarterly report, Q2 2020 — revenue $3.68B (+2% y/y), net income $1.54B, EPS $9.59 |
| Apr 23, 202010-Q | Quarterly report, Q1 2020 — revenue $3.53B (+1% y/y), net income $1.40B, EPS $8.08 |
| Apr 20, 2020DEFA14A | Additional proxy materials |
| Apr 20, 2020DEF 14A | Proxy statement |
| Feb 6, 202010-K | Annual report, FY2019 — revenue $14.38B (+7% y/y), net income $5.89B, EPS $31.42 |
11 current reports (8-K) not listed; the year is on EDGAR.
2019 · 18 filings — 10 × 8-K, 3 × 10-Q, 3 × DEFA14A and 2 other forms
| Filed | What it is |
|---|---|
| Oct 22, 201910-Q | Quarterly report, Q3 2019 — revenue $3.60B (+5% y/y), net income $1.55B, EPS $8.39 |
| Jul 24, 201910-Q | Quarterly report, Q2 2019 — revenue $3.62B (+8% y/y), net income $1.49B, EPS $7.85 |
| May 24, 2019DEFA14A | Additional proxy materials |
| Apr 30, 2019DEFA14A | Additional proxy materials |
| Apr 30, 2019DEF 14A | Proxy statement |
| Apr 29, 2019DEFA14A | Additional proxy materials |
| Apr 24, 201910-Q | Quarterly report, Q1 2019 — revenue $3.49B (+11% y/y), net income $1.41B, EPS $7.15 |
| Feb 6, 201910-K | Annual report, FY2018 — revenue $13.45B (+10% y/y), net income $4.43B, EPS $21.58 |
10 current reports (8-K) not listed; the year is on EDGAR.
2018 · 16 filings — 8 × 8-K, 3 × 10-Q, 2 × PX14A6G and 3 other forms
| Filed | What it is |
|---|---|
| Oct 23, 201810-Q | Quarterly report, Q3 2018 — revenue $3.44B (+12% y/y), net income $1.44B, EPS $7.15 |
| Jul 24, 201810-Q | Quarterly report, Q2 2018 — revenue $3.36B (+9% y/y), net income $866.6M, EPS $4.18 |
| May 3, 2018PX14A6G | Shareholder exempt solicitation |
| Apr 27, 2018DEFA14A | Additional proxy materials |
| Apr 27, 2018DEF 14A | Proxy statement |
| Apr 24, 201810-Q | Quarterly report, Q1 2018 — revenue $3.13B (+11% y/y), net income $1.17B, EPS $5.54 |
| Mar 27, 2018PX14A6G | Shareholder exempt solicitation |
| Feb 1, 201810-K | Annual report, FY2017 — revenue $12.27B (+7% y/y), net income $2.54B, EPS $11.92 |
8 current reports (8-K) not listed; the year is on EDGAR.
2017 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 24, 201710-Q | Quarterly report, Q3 2017 — revenue $3.08B (+4% y/y), net income $1.23B, EPS $5.79 |
| Jul 25, 201710-Q | Quarterly report, Q2 2017 — revenue $3.08B (+6% y/y), net income $862.8M, EPS $4.07 |
| Apr 26, 2017DEFA14A | Additional proxy materials |
| Apr 26, 2017DEF 14A | Proxy statement |
| Apr 25, 201710-Q | Quarterly report, Q1 2017 — revenue $2.81B (+3% y/y), net income $747.6M, EPS $3.46 |
| Feb 2, 201710-K | Annual report, FY2016 — revenue $11.45B (+6% y/y), net income $3.70B, EPS $16.93 |
11 current reports (8-K) not listed; the year is on EDGAR.
2016 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2015 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2014 · 13 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2013 · 18 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2012 · 16 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 5 other forms
Counted, not listed; the year is on EDGAR.
2011 · 23 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 5 other forms
Counted, not listed; the year is on EDGAR.
2010 · 28 filings — 15 × 8-K, 5 × DEFA14A, 3 × 10-Q and 4 other forms
Counted, not listed; the year is on EDGAR.
2009 · 64 filings — 28 × DEFA14A, 16 × 8-K, 8 × DFAN14A and 7 other forms
Counted, not listed; the year is on EDGAR.
2008 · 61 filings — 27 × DEFA14A, 19 × 8-K, 4 × DFAN14A and 8 other forms
Counted, not listed; the year is on EDGAR.
2007 · 17 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2006 · 17 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2005 · 31 filings — 25 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2004 · 24 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2003 · 17 filings — 9 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2001 · 7 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2000 · 5 filings — 3 × 10-Q, 1 × 10-K, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
1999 · 8 filings — 3 × 10-Q, 2 × 8-K, 2 × DEF 14A and 1 other form
Counted, not listed; the year is on EDGAR.
1998 · 6 filings — 3 × 10-Q, 1 × 10-K405, 1 × 10-K405/A and 1 other form
Counted, not listed; the year is on EDGAR.
1997 · 10 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K405 and 3 other forms
Counted, not listed; the year is on EDGAR.
1996 · 7 filings — 3 × 10-Q/A, 2 × 10-Q, 1 × 10-K/A and 1 other form
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 57 filings — 35 × 4, 4 × 144, 4 × SC TO-C and 7 other forms
| Filed | What it is |
|---|---|
| Oct 5, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Aug 12, 20263 | Initial insider holdings (Form 3) |
| Aug 6, 2026SCHEDULE 13G/A | Other filings |
| Aug 5, 20264 | Insider transaction (Form 4) |
| Aug 4, 2026144 | Notice of proposed sale (Form 144) |
| Aug 3, 2026144 | Notice of proposed sale (Form 144) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 11, 20264 | Insider transaction (Form 4) |
| Jun 5, 2026SCHEDULE 13G/A | Other filings |
| May 14, 2026SCHEDULE 13D/A | Other filings |
| May 14, 2026SC TO-T/A | Beneficial ownership |
| May 12, 2026SC TO-T/A | AMENDMENT NO. 2 |
| May 6, 2026SC TO-T/A | AMENDMENT NO. 1 |
| May 6, 2026SCHEDULE 13G/A | Other filings |
| May 5, 20264 | Insider transaction (Form 4) |
| Apr 29, 2026SCHEDULE 13G | Other filings |
| Apr 14, 2026SC TO-T | Beneficial ownership |
The newest 25 of 57 shown; the full year is on EDGAR.
2025 · 55 filings — 39 × 4, 4 × 144, 2 × 3 and 7 other forms
| Filed | What it is |
|---|---|
| Dec 3, 20254 | Insider transaction (Form 4) |
| Nov 13, 2025SCHEDULE 13G/A | Other filings |
| Nov 10, 2025SCHEDULE 13G | Other filings |
| Nov 4, 20254 | Insider transaction (Form 4) |
| Oct 6, 20254 | Insider transaction (Form 4) |
| Sep 2, 20254 | Insider transaction (Form 4) |
| Sep 2, 2025144 | Notice of proposed sale (Form 144) |
| Jul 30, 2025SCHEDULE 13D/A | Other filings |
| Jul 21, 2025SCHEDULE 13D/A | Other filings |
| Jul 16, 20254 | Insider transaction (Form 4) |
| Jul 8, 2025144 | Notice of proposed sale (Form 144) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| Jun 18, 20254 | Insider transaction (Form 4) |
| May 20, 20254 | Insider transaction (Form 4) |
| May 19, 2025144 | Notice of proposed sale (Form 144) |
| May 8, 2025424B2 | Prospectus supplement |
| May 6, 2025FWP | Free writing prospectus |
The newest 25 of 55 shown; the full year is on EDGAR.
2024 · 72 filings — 50 × 4, 11 × SC 13G/A, 7 × 144 and 3 other forms
| Filed | What it is |
|---|---|
| Dec 9, 20244 | Insider transaction (Form 4) |
| Dec 9, 20244 | Insider transaction (Form 4) |
| Dec 9, 2024144 | Notice of proposed sale (Form 144) |
| Nov 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 7, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 7, 20244 | Insider transaction (Form 4) |
| Nov 4, 20244 | Insider transaction (Form 4) |
| Nov 4, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Oct 16, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Oct 7, 20243 | Initial insider holdings (Form 3) |
| Sep 5, 20244 | Insider transaction (Form 4) |
| Sep 3, 2024144 | Notice of proposed sale (Form 144) |
| Aug 16, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Aug 7, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 25, 20244 | Insider transaction (Form 4) |
| Jun 20, 2024S-8 | Employee stock plan registration |
| May 3, 20244 | Insider transaction (Form 4) |
| Apr 3, 20244 | Insider transaction (Form 4) |
The newest 25 of 72 shown; the full year is on EDGAR.
2023 · 67 filings — 49 × 4, 6 × 144, 5 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2022 · 64 filings — 51 × 4, 3 × SC 13G/A, 2 × 3 and 7 other forms
Counted, not listed; the year is on EDGAR.
2021 · 64 filings — 47 × 4, 4 × 3, 4 × UPLOAD and 4 other forms
Counted, not listed; the year is on EDGAR.
2020 · 49 filings — 33 × 4, 6 × SC 13G/A, 3 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2019 · 51 filings — 43 × 4, 3 × 3, 3 × SC 13G/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2018 · 56 filings — 47 × 4, 2 × 3, 2 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2017 · 61 filings — 47 × 4, 4 × 3, 3 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2016 · 85 filings — 73 × 4, 5 × SC 13G/A, 4 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2015 · 93 filings — 81 × 4, 3 × SC 13G, 3 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2014 · 89 filings — 83 × 4, 4 × SC 13G/A, 2 × 3
Counted, not listed; the year is on EDGAR.
2013 · 93 filings — 83 × 4, 4 × SC 13G/A, 2 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2012 · 97 filings — 78 × 4, 8 × SC 13G/A, 3 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2011 · 97 filings — 80 × 4, 6 × SC 13G/A, 3 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2010 · 91 filings — 61 × 4, 7 × 3, 7 × UPLOAD and 6 other forms
Counted, not listed; the year is on EDGAR.
2009 · 88 filings — 62 × 4, 7 × SC TO-T/A, 4 × SC 13G/A and 9 other forms
Counted, not listed; the year is on EDGAR.
2008 · 131 filings — 94 × 4, 9 × 4/A, 5 × SC 13G/A and 13 other forms
Counted, not listed; the year is on EDGAR.
2007 · 143 filings — 124 × 4, 5 × SC 13G/A, 3 × SC TO-I/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2006 · 115 filings — 71 × 4, 26 × 4/A, 7 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2005 · 83 filings — 61 × 4, 5 × 3, 5 × 4/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2004 · 156 filings — 135 × 4, 10 × 4/A, 5 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2003 · 79 filings — 29 × 4, 20 × 425, 11 × 3 and 9 other forms
Counted, not listed; the year is on EDGAR.
2002 · 13 filings — 6 × 424B3, 3 × SC 13G/A, 1 × POS AM and 3 other forms
Counted, not listed; the year is on EDGAR.
2001 · 7 filings — 4 × SC 13G/A, 1 × 8-A12G/A, 1 × S-8 and 1 other form
Counted, not listed; the year is on EDGAR.
2000 · 17 filings — 7 × SC 13G/A, 4 × 424B3, 2 × S-3/A and 3 other forms
Counted, not listed; the year is on EDGAR.
1999 · 13 filings — 4 × SC 13G/A, 3 × SC 13G, 2 × 424B3 and 4 other forms
Counted, not listed; the year is on EDGAR.
1998 · 12 filings — 4 × SC 13G, 3 × SC 13G/A, 1 × RW and 4 other forms
Counted, not listed; the year is on EDGAR.
1997 · 11 filings — 4 × SC 13D/A, 2 × SC 13G, 1 × 8-A12B and 4 other forms
Counted, not listed; the year is on EDGAR.
1996 · 12 filings — 2 × 424B4, 2 × S-3/A, 2 × SC 13D/A and 6 other forms
Counted, not listed; the year is on EDGAR.
About this data#
Biogen Inc. (BIIB) has 2,712 filings on EDGAR going back to 1996: 34 annual reports, 95 quarterly reports and 298 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 6, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Jul 29, 2026, covered results of operations. Over the last 13 months insiders sold $905K in 4 sales and bought $585 in 1 purchase; 65 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Biogen Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read BIIB's latest 10-K?
- BIIB's latest annual report, a 10-K, was filed on Feb 6, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did BIIB last file an 8-K?
- On Jul 29, 2026 it covered results of operations. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 29, 2026.
- Are BIIB insiders buying or selling?
- Over the last 13 months insiders sold $905K in 4 sales and bought $585 in 1 purchase; 65 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Minor Lloyd (Director) sold 593 shares on Aug 4, 2026 for $119K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has BIIB made?
- 2,712 filings are on EDGAR under the registrant records that have been Biogen Inc., going back to 1996; 1,734 of them are insider ownership forms (Forms 3, 4, 5 and 144).